Evidence map›Paper›PMID 25815346›Full record

ArticleJournal of immunology research2015

Effective binding of a phosphatidylserine-targeting antibody to Ebola virus infected cells and purified virions.

S D Dowall, V A Graham, K Corbin-Lickfett, C Empig, K Schlunegger, C B Bruce, L Easterbrook, R Hewson

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of immunology research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Importance of Efferocytosis in COVID-19 Mortality.Infection and drug resistance · 2022
    Review
  3. Article
  4. Review
  5. Review
  6. Plasma lipidome reveals critical illness and recovery from human Ebola virus disease.Proceedings of the National Academy of Sciences of the United States of America · 2019
    Article
  7. Review
  8. Review
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 2 countries.

S D DowallPublic Health England, Porton Down, Wiltshire, Salisbury SP4 0JG, UK.
V A GrahamPublic Health England, Porton Down, Wiltshire, Salisbury SP4 0JG, UK.
K Corbin-LickfettPeregrine Pharmaceuticals, Inc., Tustin, CA 92780, USA.
C EmpigPeregrine Pharmaceuticals, Inc., Tustin, CA 92780, USA.
K SchluneggerPeregrine Pharmaceuticals, Inc., Tustin, CA 92780, USA.
C B BrucePublic Health England, Porton Down, Wiltshire, Salisbury SP4 0JG, UK.
L EasterbrookPublic Health England, Porton Down, Wiltshire, Salisbury SP4 0JG, UK.
R HewsonPublic Health England, Porton Down, Wiltshire, Salisbury SP4 0JG, UK.
Public Health England · GBAvid Bioservices (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ebola virus is responsible for causing severe hemorrhagic fevers, with case fatality rates of up to 90%. Currently, no antiviral or vaccine is licensed against Ebola virus. A phosphatidylserine-targeting antibody (PGN401, bavituximab) has previously been shown to have broad-spectrum antiviral activity. Here, we demonstrate that PGN401 specifically binds to Ebola virus and recognizes infected cells. Our study provides the first evidence of phosphatidylserine-targeting antibody reactivity against Ebola virus.

Indexed as

AnimalsAntibodies, ViralCell LineCells, CulturedChlorocebus aethiopsEbolavirusFlow CytometryFluorescent Antibody TechniqueHemorrhagic Fever, EbolaHumansPhosphatidylserinesProtein BindingVero CellsVirionAntibodies, ViralPhosphatidylserines

Identifiers

PMID25815346
PMCPMC4359806
OpenAlexW2085614330

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.